Literature DB >> 22345499

Dabigatran (Pradaxa).

J Comin1, D F Kallmes.   

Abstract

Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22345499      PMCID： PMC7966436          DOI： 10.3174/ajnr.A3000

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  12 in total

1.  Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Authors:  James V Freeman; Ruo P Zhu; Douglas K Owens; Alan M Garber; David W Hutton; Alan S Go; Paul J Wang; Mintu P Turakhia
Journal:  Ann Intern Med       Date:  2010-11-01       Impact factor: 25.391

2.  Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation.

Authors:  Greg Flaker; Richard Weachter
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

3.  Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.

Authors:  Karl-Heinz Liesenfeld; Hans G Schäfer; Iñaki F Trocóniz; Christiane Tillmann; Bengt I Eriksson; Joachim Stangier
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

Review 4.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

5.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

6.  Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.

Authors:  Arne Lauer; Flor A Cianchetti; Elizabeth M Van Cott; Frieder Schlunk; Elena Schulz; Waltraud Pfeilschifter; Helmuth Steinmetz; Chris B Schaffer; Eng H Lo; Christian Foerch
Journal:  Circulation       Date:  2011-09-12       Impact factor: 29.690

Review 7.  Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors:  Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha.

Authors:  Reha Celikel; Richard A McClintock; James R Roberts; G Loredana Mendolicchio; Jerry Ware; Kottayil I Varughese; Zaverio M Ruggeri
Journal:  Science       Date:  2003-07-11       Impact factor: 47.728

9.  Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Authors:  Joachim Stangier; Hildegard Stähle; Karin Rathgen; Reinhold Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335
View more
  3 in total

1.  Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet.

Authors:  Naoto Ishikawa; Hanae Oshikiri; Shinya Takasaki; Masafumi Kikuchi; Taku Obara; Kazutoshi Akasaka; Masaki Matsuura; Hiroaki Yamaguchi; Nariyasu Mano
Journal:  J Pharm Health Care Sci       Date:  2021-06-01

2.  Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations.

Authors:  Xiaoping Xu; Qian Liang
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 3.  Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions.

Authors:  Natalia A Shnayder; Marina M Petrova; Pavel A Shesternya; Alina V Savinova; Elena N Bochanova; Olga V Zimnitskaya; Elena A Pozhilenkova; Regina F Nasyrova
Journal:  Biomedicines       Date:  2021-04-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.